<DOC>
	<DOCNO>NCT01653379</DOCNO>
	<brief_summary>This open-label , dose-ranging study vitamin D analog DP001 patient end-stage renal disease ( ESRD ) . The primary goal 4-week Phase 2A study identify appropriate start dose DP001 use subsequent study population evaluation pharmacokinetics DP001 ESRD patient .</brief_summary>
	<brief_title>A Phase 2A Dose-ranging Pharmacokinetic Study Oral Vitamin D Compound ( DP001 ) Secondary Hyperparathyroidism</brief_title>
	<detailed_description>Vitamin D hormone analog , bound vitamin D receptor , suppress PTH synthesis bind negative regulatory element promoter PTH gene , use successfully clinic reduce elevate PTH level dialysis patient CKD patient . DP001 highly potent vitamin D compound . In two clinical trial test DP001 postmenopausal woman , oral DP001 reduce PTH level dose-dependent manner , dose 220 ng lower PTH least 30 % majority patient follow one six month daily dose . This study open-label , dose-ranging study DP001 ESRD patient secondary hyperparathyroidism . Cohorts 6 patient enrol administered oral DP001 110 ng three time per week four week . Laboratory data cohort assess used determine dose next cohort . Up 5 dose-ranging cohort study , goal identify appropriate dose randomize , placebo-controlled study oral DP001 12 week . The data also use select appropriate dose additional cohort 12 open-label patient current study pharmacokinetics DP001 follow single dose repeat dos study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>Patient diagnose ESRD must hemodialysis 3 time per week least 3 month Plasma intact PTH value &gt; /= 300 pg/mL Currently take drug affect vitamin D metabolism History symptomatic ventricular dysrhythmias , congestive heart failure , angina pectoris , myocardial infarction , coronary angioplasty , coronary artery bypass graft Active malignancy Clinically significant liver disease Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>